India · Delayed Price · Currency is INR Marksans Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Record FY 2026 results with net income above INR 3,000 crore, strong growth in North America, and margin expansion. Guidance targets INR 4,000 crore revenue by FY 2028, with robust product pipeline and ongoing M&A focus.
-
Q3 FY26 saw record revenue and margin expansion, led by strong US growth and stabilization in the UK. The company remains debt-free, with robust cash reserves, and is targeting INR 4,000 crore revenue in 2-3 years, supported by a strong order book and ongoing expansion in Europe and Canada.
-
Q2 FY 2026 delivered strong sequential and year-on-year growth, with robust U.S. and U.K. performance, improved margins, and a healthy order book. Expansion in Europe and capacity investments are underway, while tariff risks have eased and guidance remains positive for FY 2026.
-
Q1 FY26 saw 5% revenue growth and gross margin expansion, but profitability was impacted by one-time costs and UK price erosion. US business grew 30% year-on-year, while UK and Australia faced seasonal and pricing headwinds. Outlook remains cautious amid tariff uncertainties.
Fiscal Year 2025
-
Record revenue and profit growth in FY2025 was led by strong U.S. and OTC segment performance, with gross margin expansion and robust product pipeline execution. Management is confident of achieving INR 3,000 crore revenue in FY2026, with operating leverage and new launches expected to drive further margin improvement.
-
Q3 FY25 saw record PAT and 16.3% revenue growth, led by a 37% surge in U.S. sales. Gross margin expanded to 56.2%, while EBITDA margin dipped due to higher costs from facility ramp-up. Outlook remains strong with capacity and product pipeline supporting future growth.
-
Q2 FY25 saw 20.8% revenue growth year-on-year, led by the U.S. and supported by new product launches and improved margins. The Teva facility ramped up, contributing INR 100 crores, and the company remains debt-free with strong cash reserves. Outlook remains positive with a target of INR 3,000 crores revenue in two years.
-
Q1 FY25 delivered robust revenue and profit growth, led by strong U.S. and U.K. performance, margin expansion, and successful ramp-up of the new facility. Freight costs remain a challenge, but management expects continued growth and targets INR 3,000 crore revenue in two years.